Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagenic Therapeutics Inc

2.85
-0.3000-9.52%
Pre-market: 2.82-0.0300-1.05%07:00 EDT
Volume:147.75K
Turnover:439.57K
Market Cap:2.47M
PE:-0.22
High:3.10
Open:3.05
Low:2.85
Close:3.15
52wk High:15.54
52wk Low:2.25
Shares:868.41K
Float Shares:771.10K
Volume Ratio:1.20
T/O Rate:19.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0507
EPS(LYR):-15.7868
ROE:-512.79%
ROA:-189.60%
PB:-28.02
PE(LYR):-0.18

Loading ...

Top Midday Gainers

MT Newswires Live
·
Aug 22

Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress & Mood Disorders Set for 1Q 2026

Reuters
·
Aug 21

Protagenic Therapeutics Inc. Delays Q2 Financial Report Due to Transition to Virtual Operating Model

Reuters
·
Aug 15

BRIEF-Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC Filing

Reuters
·
Aug 14

Protagenic Therapeutics to Pause Trials, Remove CEO in Restructuring

Dow Jones
·
Aug 14

Protagenic Therapeutics Inc: Has Temporarily Suspended Expenditures Related to Preclinical Programs

THOMSON REUTERS
·
Aug 14

Protagenic Therapeutics : Terminated Employment of Barrett Evans as CEO and President and Colin Stott as Chief Operating Officer

THOMSON REUTERS
·
Aug 14

Protagenic Therapeutics:All Preclinical Programs Originated With Former Phytanix Bio (Phyx-001,Phyx-002,Phyx-003,Phyx-004, Phyx-005) Have Been Paused

THOMSON REUTERS
·
Aug 14

Protagenic Therapeutics Inc: Initiated Process to Evaluate Strategic Alternatives for Those Programs, Including Partnerships and/or Out-Licensing

THOMSON REUTERS
·
Aug 14

Protagenic Therapeutics Inc: Approved a Change in Co's Fiscal Year-End From December 31 to March 31, Effective Immediately

THOMSON REUTERS
·
Aug 14

Protagenic Therapeutics : When Fully Implemented, Restructuring Plan Is Expected to Reduce Annualized Operating Expenses by About $8 Mln

THOMSON REUTERS
·
Aug 14

Protagenic Therapeutics Inc: Reducing Operating Expenses, Overhead, and Headcount Primarily Associated With Preclinical Activities

THOMSON REUTERS
·
Aug 14

Protagenic Therapeutics Inc: Restructuring Plan to Transition to Virtual Operating Model, Concentrate Capital on Highest-Priority Clinical Program(S)

THOMSON REUTERS
·
Aug 14

Protagenic Therapeutics Inc. Announces Corporate Restructuring, Shifts to Virtual Operating Model and Streamlines Focus on Key Clinical Program

Reuters
·
Aug 14

Protagenic Therapeutics Inc. Secures Patent in Japan for Innovative Modified Stilbenoid Program Drug Candidates

Reuters
·
Jul 31

BRIEF-Protagenic Therapeutics Granted Japanese Patent JP 7714571B

Reuters
·
Jul 30

Protagenic Therapeutics Inc. Appoints Timothy R. Wright as Independent Director to Board

Reuters
·
Jul 25

Alterola Biotech Inc. Announces Major Management Reshuffle as Top Executives Resign

Reuters
·
Jun 30

Protagenic Therapeutics Inc. Announces Plan for Stock Rights Distribution Following Phytanix Acquisition

Reuters
·
Jun 28